Anthony Vendetti Maintains Buy on NeuroOne, Reaffirms $5 Price Target on Growing Product Momentum and Diversified Neuro Ablation Pipeline

Maxim Group analyst Anthony Vendetti has maintained their bullish stance on NMTC stock, giving a Buy rating yesterday.

Claim 55% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Anthony Vendetti has given his Buy rating due to a combination of factors tied to NeuroOne’s commercial progress and technology pipeline. Despite a recent revenue miss and lowered guidance, he highlights strong product order momentum, growing backlog, and ongoing adoption of the OneRF Trigeminal Nerve Ablation System, supported by a shift toward a regional distributor model and new ISO 13485 certification that should unlock international market opportunities by 2026.

Vendetti also points to multiple emerging clinical platforms—StereoCED for targeted brain drug delivery, the Basivertebral Nerve Ablation System for lower back pain, and OneRF Brain Ablation—all of which broaden the company’s potential revenue streams across several neurological indications. Coupled with adequate capital to fund operations, a diversified growth pipeline, and a valuation that he views as attractive versus peers based on his DCF and EV/revenue analysis, these elements underpin his decision to maintain a Buy rating and a $5 price target.

In another report released yesterday, Ladenburg Thalmann & Co. also reiterated a Buy rating on the stock with a $8.80 price target.